Ligand Pharmaceuticals Reports Third-Quarter 2026 Results

Revenue was $78.75 million and net loss was $28.49 million, compared with $115.46 million in revenue and $117.27 million in net income a year earlier. Diluted loss per share was $1.43, versus diluted earnings per share of $5.68.